The Cancer News
AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Perspectives
This section features opinion pieces, reflections, and expert commentary on timely or overlooked issues in cancer care, research, and the oncology workforce.
2025 Oncology Year in Review: Breakthrough Cancer Treatments and Research
By Aishat Motolani, PhD
A comprehensive 2025 oncology year in review exploring breakthroughs in cancer treatment, AI in oncology, immunotherapy approvals, liquid biopsy debates, mRNA vaccines, and global cancer health equity.
2025 Oncology Year in Review: Breakthrough Cancer Treatments and Research
By Aishat Motolani, PhD
A comprehensive 2025 oncology year in review exploring breakthroughs in cancer treatment, AI in oncology, immunotherapy approvals, liquid biopsy debates, mRNA vaccines, and global cancer health equity.
2025 Oncology Year in Review: Breakthrough Cancer Treatments and Research
By Aishat Motolani, PhD
A comprehensive 2025 oncology year in review exploring breakthroughs in cancer treatment, AI in oncology, immunotherapy approvals, liquid biopsy debates, mRNA vaccines, and global cancer health equity.
San Antonio Breast Cancer Symposium 2025: Oncologist's Review of Key Trial Results and Therapeutic Advances
By Dr. Milana Dolezal
An oncologist’s expert review of pivotal clinical trials and therapeutic advances in early and metastatic breast cancer presented at the San Antonio Breast Cancer Symposium 2025.
San Antonio Breast Cancer Symposium 2025: Oncologist's Review of Key Trial Results and Therapeutic Advances
By Dr. Milana Dolezal
An oncologist’s expert review of pivotal clinical trials and therapeutic advances in early and metastatic breast cancer presented at the San Antonio Breast Cancer Symposium 2025.
San Antonio Breast Cancer Symposium 2025: Oncologist's Review of Key Trial Results and Therapeutic Advances
By Dr. Milana Dolezal
An oncologist’s expert review of pivotal clinical trials and therapeutic advances in early and metastatic breast cancer presented at the San Antonio Breast Cancer Symposium 2025.
Understanding PALB2 Mutations in Pancreatic Cancer
By Jonathan W Lee, MD, MSc
November marks Pancreatic Cancer Awareness Month, a time to shine a light on one of oncology's most challenging diseases.
Understanding PALB2 Mutations in Pancreatic Cancer
By Jonathan W Lee, MD, MSc
November marks Pancreatic Cancer Awareness Month, a time to shine a light on one of oncology's most challenging diseases.
Understanding PALB2 Mutations in Pancreatic Cancer
By Jonathan W Lee, MD, MSc
November marks Pancreatic Cancer Awareness Month, a time to shine a light on one of oncology's most challenging diseases.
Palo Alto VA and Stanford Oncologist Advancing Cancer Care
By The Cancer News Team
Dr. Millie Das, Chief of Oncology at the Palo Alto VA and Stanford oncologist, advances precision oncology through clinical trial access and leadership in targeted therapies.
Palo Alto VA and Stanford Oncologist Advancing Cancer Care
By The Cancer News Team
Dr. Millie Das, Chief of Oncology at the Palo Alto VA and Stanford oncologist, advances precision oncology through clinical trial access and leadership in targeted therapies.
Palo Alto VA and Stanford Oncologist Advancing Cancer Care
By The Cancer News Team
Dr. Millie Das, Chief of Oncology at the Palo Alto VA and Stanford oncologist, advances precision oncology through clinical trial access and leadership in targeted therapies.
World Cancer Research Day 2025: Progress, Challenges, and What’s Next in U.S. Cancer Research
By Aishat Motolani, PhD
Explore the progress, challenges, and future directions of U.S. cancer research on World Cancer Research Day 2025, from immunotherapy and RNA vaccines to AI, prevention, and health equity.
World Cancer Research Day 2025: Progress, Challenges, and What’s Next in U.S. Cancer Research
By Aishat Motolani, PhD
Explore the progress, challenges, and future directions of U.S. cancer research on World Cancer Research Day 2025, from immunotherapy and RNA vaccines to AI, prevention, and health equity.
World Cancer Research Day 2025: Progress, Challenges, and What’s Next in U.S. Cancer Research
By Aishat Motolani, PhD
Explore the progress, challenges, and future directions of U.S. cancer research on World Cancer Research Day 2025, from immunotherapy and RNA vaccines to AI, prevention, and health equity.
Melanoma Monday 2025: On Skin Cancer Prevention & Awareness
By The Cancer News Team
This article spotlights Melanoma Monday 2025 with expert insights from Dr. Shailender Bhatia on melanoma prevention, early detection, and treatment advancements.
Melanoma Monday 2025: On Skin Cancer Prevention & Awareness
By The Cancer News Team
This article spotlights Melanoma Monday 2025 with expert insights from Dr. Shailender Bhatia on melanoma prevention, early detection, and treatment advancements.
Melanoma Monday 2025: On Skin Cancer Prevention & Awareness
By The Cancer News Team
This article spotlights Melanoma Monday 2025 with expert insights from Dr. Shailender Bhatia on melanoma prevention, early detection, and treatment advancements.
Implementation Science In Cancer: Where Are We Today?
By The Cancer News Team
This article explores implementation science in cancer care, with insights from Fred Hutch’s Dr. Mazyar Shadman and the efforts of Binaytara and Dr. Binay Shah to reduce cancer disparities in LMICs.
Implementation Science In Cancer: Where Are We Today?
By The Cancer News Team
This article explores implementation science in cancer care, with insights from Fred Hutch’s Dr. Mazyar Shadman and the efforts of Binaytara and Dr. Binay Shah to reduce cancer disparities in LMICs.
Implementation Science In Cancer: Where Are We Today?
By The Cancer News Team
This article explores implementation science in cancer care, with insights from Fred Hutch’s Dr. Mazyar Shadman and the efforts of Binaytara and Dr. Binay Shah to reduce cancer disparities in LMICs.
Zuma 7 trial shows statistically significant overall survival benefit for yescarta
By Editorial Team
By Dr. Luke Fletcher [Willamette Valley Cancer Institute & Research Center](https://www.oregoncancer.com/) _The Zuma 7 trial is a randomized, open-label multicenter study for patients with primary ref...
Zuma 7 trial shows statistically significant overall survival benefit for yescarta
By Editorial Team
By Dr. Luke Fletcher [Willamette Valley Cancer Institute & Research Center](https://www.oregoncancer.com/) _The Zuma 7 trial is a randomized, open-label multicenter study for patients with primary ref...
Zuma 7 trial shows statistically significant overall survival benefit for yescarta
By Editorial Team
By Dr. Luke Fletcher [Willamette Valley Cancer Institute & Research Center](https://www.oregoncancer.com/) _The Zuma 7 trial is a randomized, open-label multicenter study for patients with primary ref...
Volunteer Spotlight: June Zhu
By The Cancer News Team
Zhu Shares About Her Experience Volunteering at Binaytara
Volunteer Spotlight: June Zhu
By The Cancer News Team
Zhu Shares About Her Experience Volunteering at Binaytara
Volunteer Spotlight: June Zhu
By The Cancer News Team
Zhu Shares About Her Experience Volunteering at Binaytara